andrew huberman retatrutide The Next Ozempic Isn't Just About Weight Loss It's About Rewriting Human Performance Andrew D. Huberman, Ph.D.'s Video

Microdosing GLP1s for Menopause In an effort to minimize side effects (and in some cases, reduce cost), some women are turning to microdosing GLP-1s for menopause weight loss

In HepG2 and Huh7 cells expressing GLP-1R, exendin-4 treatment led to the phosphorylation of key mediators of the insulin-signaling pathway

Knowing how long a GLP-1 agonist stays in your body is fundamental to managing expectations, ensuring safety, and maximizing the incredible benefits these therapies offer

But in a context where coverage of GLP-1s is not required, (although in a recent column it was proposed that anti-obesity medications should be considered preventive by the US Preventive Services Task Force) an insurer might fear adverse selection if they covered the medications while their competitors did not

The event focused on new agreements with Eli Lilly and Novo Nordisk